Identify amenable GLA variants
In the search bar, enter either a DNA or protein change to determine amenability.
In the search bars below, enter up to 3 GLA variants to determine amenability.
You can use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information as amenable to treatment with Galafold. The current list of amenable GLA variants can also be found in the Full Prescribing Information.
Whether a certain amenable GLA variant in a patient with Fabry disease is disease-causing or not should be determined by the prescribing physician (in consultation with a clinical genetics professional, if needed) prior to treatment initiation. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).
In the search bar, enter either a DNA or protein change to determine amenability.
You can use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information as amenable to treatment with Galafold. The current list of amenable GLA variants can also be found in the Full Prescribing Information.
This search bar is intended only for Healthcare Professionals licensed to practice in the United States.
For DNA Change
Please use format c.#A>B or c.A#B for DNA changes, where 'c.' is optional; # indicates a number; A and B are letters. Examples: c.8T>C or c.T8C
For Protein Change
Protein changes can be written as either a single-letter or three-letter code. For example, p.(L3P) can be written as is or written as p.(Leu3Pro), where the ‘p.’ and ‘()’ are optional in both cases.
Whether a certain amenable GLA variant in a patient with Fabry disease is disease-causing or not should be determined by the prescribing physician (in consultation with a clinical genetics professional, if needed) prior to treatment initiation. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).
In the search bars below, enter up to 3 GLA variants to determine amenability.
You can use this search tool to find out whether a specific GLA variant has been listed in the Full Prescribing Information as amenable to treatment with Galafold. The current list of amenable GLA variants can also be found in the Full Prescribing Information.
This search bar is intended only for Healthcare Professionals licensed to practice in the United States.
For DNA Change
Please use format c.#A>B or c.A#B for DNA changes, where 'c.' is optional; # indicates a number; A and B are letters. Examples: c.8T>C or c.T8C
For Protein Change
Protein changes can be written as either a single-letter or three-letter code. For example, p.(L3P) can be written as is or written as p.(Leu3Pro), where the ‘p.’ and ‘()’ are optional in both cases.
Whether a certain amenable GLA variant in a patient with Fabry disease is disease-causing or not should be determined by the prescribing physician (in consultation with a clinical genetics professional, if needed) prior to treatment initiation. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).
INDICATIONS AND USAGE
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
You can also determine whether your patient's GLA variant is amenable by:
The Galafold Full Prescribing Information includes a list of GLA variants that have been identified as amenable to Galafold.
For answers to questions about amenability, you can also contact Amicus Medical Information at
1-877-4-AMICUS or MedInfoUSA@amicusrx.com.
Help your patients determine if their GLA variant is amenable to Galafold
Learn more about Fabry
disease at FabryFacts.com
Understand more about the complexities of this disease, including signs, symptoms, how diagnosis can vary between genders, and much more.
Download the Galafold
Patient Referral Form
This form serves a dual purpose: as a prescription for Galafold in some states and as a way for patients to register for AMICUS ASSIST®.